A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
- PMID: 27712635
- DOI: 10.1016/j.mayocp.2016.06.024
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
Erratum in
-
Correction.Mayo Clin Proc. 2016 Dec;91(12):1843. doi: 10.1016/j.mayocp.2016.11.002. Mayo Clin Proc. 2016. PMID: 27916160 No abstract available.
Abstract
Objective: To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE).
Patients and methods: A multinational retrospective cohort study (INCREMENT project) was performed from January 1, 2004, through December 31, 2013. Patients with clinically relevant monomicrobial BSIs due to CPE were included and randomly assigned to either a derivation cohort (DC) or a validation cohort (VC). The variables were assessed on the day the susceptibility results were available, and the predictive score was developed using hierarchical logistic regression. The main outcome variable was 14-day all-cause mortality. The predictive ability of the model and scores were measured by calculating the area under the receiver operating characteristic curve. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for different cutoffs of the score.
Results: The DC and VC included 314 and 154 patients, respectively. The final logistic regression model of the DC included the following variables: severe sepsis or shock at presentation (5 points); Pitt score of 6 or more (4 points); Charlson comorbidity index of 2 or more (3 points); source of BSI other than urinary or biliary tract (3 points); inappropriate empirical therapy and inappropriate early targeted therapy (2 points). The score exhibited an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.74-0.85) in the DC and 0.80 (95% CI, 0.73-0.88) in the VC. The results for 30-day all-cause mortality were similar.
Conclusion: A validated score predictive of early mortality in patients with BSIs due to CPE was developed.
Trial registration: clinicaltrials.gov Identifier: NCT01 764490.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.J Antimicrob Chemother. 2017 Mar 1;72(3):906-913. doi: 10.1093/jac/dkw513. J Antimicrob Chemother. 2017. PMID: 28062685 Free PMC article.
-
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22. Lancet Infect Dis. 2017. PMID: 28442293
-
Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea.Antimicrob Resist Infect Control. 2019 Mar 5;8:48. doi: 10.1186/s13756-019-0497-3. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 30873279 Free PMC article.
-
Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.Future Microbiol. 2012 Oct;7(10):1173-89. doi: 10.2217/fmb.12.100. Future Microbiol. 2012. PMID: 23030423 Review.
-
Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis.Enferm Infecc Microbiol Clin. 2014 Dec;32 Suppl 4:41-8. doi: 10.1016/S0213-005X(14)70173-9. Enferm Infecc Microbiol Clin. 2014. PMID: 25542051 Review.
Cited by
-
Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization.JAC Antimicrob Resist. 2023 Aug 10;5(4):dlad096. doi: 10.1093/jacamr/dlad096. eCollection 2023 Aug. JAC Antimicrob Resist. 2023. PMID: 37577156 Free PMC article.
-
Ceftazidime/Avibactam, Polymyxin or Tigecycline as a Rescue Strategy for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae in Bloodstream Infection: A Retrospective Cohort Study.Infect Drug Resist. 2023 May 12;16:2963-2971. doi: 10.2147/IDR.S409506. eCollection 2023. Infect Drug Resist. 2023. PMID: 37201125 Free PMC article.
-
Clinical and Genomic Evolution of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections over Two Time Periods at a Tertiary Care Hospital in South India: A Prospective Cohort Study.Infect Dis Ther. 2023 May;12(5):1319-1335. doi: 10.1007/s40121-023-00803-3. Epub 2023 Apr 16. Infect Dis Ther. 2023. PMID: 37062023 Free PMC article.
-
Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation.Antibiotics (Basel). 2023 Jan 20;12(2):226. doi: 10.3390/antibiotics12020226. Antibiotics (Basel). 2023. PMID: 36830136 Free PMC article.
-
Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure.Microbiol Spectr. 2023 Feb 14;11(1):e0264722. doi: 10.1128/spectrum.02647-22. Epub 2023 Jan 9. Microbiol Spectr. 2023. PMID: 36622246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
